United States · Bill · S
S. 898 (117th)
Fair Accountability and Innovative Research Drug Pricing Act of 2021
Introduced
23 March 2021
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
—
Subjects
Discovery layer
Source updated
21 April 2025
Summary
Fair Accountability and Innovative Research Drug Pricing Act of 20 21 This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 23 March 2021
Introduced in Senate (PDF)
Introduced in Senate · EN · 23 March 2021
Introduced in Senate
summary · EN · 23 March 2021
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/senate-bill/898
- Open data entity: https://api.congress.gov/v3/bill/117/s/898